Aurora cannabis announces fiscal 2021 fourth quarter results

Nasdaq | tsx: acb #1 canadian lp in global medical cannabis; total medical cannabis net revenue rose 9% compared to prior year; strong adjusted gross margin before fva of 68% business transformation plan on track; reiterates annual cost savings of $60 million to $80 million, providing clear pathway to adjusted ebitda profitability balance sheet remains strong with $440.9 million of cash at june 30, 2021; working capital improves by $404.3 million compared to prior year adjusted ebitda loss, excluding restructuring costs, narrows to $13.9 million, a $17.6 million improvement compared  to prior year total cannabis net revenue, net of provisions, of $54.8 million compared to $55.2 million in the prior quarter, and $67.5 million in the year-ago period edmonton, ab, sept. 27, 2021 /prnewswire/ - aurora cannabis inc. (the "company" or "aurora") (nasdaq: acb) (tsx: acb), the canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the fourth quarter and full year fiscal 2021 ended june 30, 2021.
ACB Ratings Summary
ACB Quant Ranking